Business
Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) ALACHUA, Fla. and TAMPA, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ:
About this update from Axogen, Inc.
[{"type":"text","content":"Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)\nALACHUA, Fla. and TAMPA, Fla., March 06, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Marc Began as Executive Vice President. Additionally, effective March 20, 2023, Mr. Began will be Axogen’s General Counsel, replacing Brad Ottinger, General Counsel and Chief Compliance Officer. As a member of the executive leadership team, Mr. Began will report directly to Karen Zaderej, Chairman, CEO and President, and will be responsible for all legal, business development, and compliance activities for Axogen. “I want to thank Brad for his important contributions to Axogen, and welcome Marc to our team,” commented Ms. Zaderej. “Marc’s advisory background and breadth of legal experience within biotechnology companies will bring immediate value and is an ideal addition to our team.” Marc Began has supported pharmaceuticals, medical devices, and biotechnology companies as a lawyer for more than 20 years. Mr. Began was most recently Executive Vice President, General Counsel, and Secretary of Abiomed until the completion of its acquisition by Johnson & Johnson late last year. Prior to Abiomed, he was Vice President of Intellectual Property with Boehringer Ingelheim, responsible for all medical device, pharmaceutical, and biologic intellectual property issues. Before joining Boehringer Ingelheim, Mr. Began spent 15 years in various positions of increasing responsibility at Novo Nordisk, culminating as Assistant General Counsel, where he oversaw complex litigation matters and supported business development transactions. Prior to that role, as Assistant Chief Intellectual Property Counsel, he managed global patent portfolios and enforcement strategy. Before joining Novo Nordisk, Mr. Began was an associate at the law firms of Sullivan & Cromwell and White & Case in New York where he handled a broad range of legal matters, including litigation, intellectual property, corporate transactions, regulatory and compliance. “Axogen has an impressive history and product portfolio, providing innovative solutions for patients with peripheral nerve injuries, and I look forward to working with the team,” said Mr. Began. Mr. Began earned a Juris ...